»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
°³¿ä
½ÅÀå ÀÌ½Ä Ä¡·áÁ¦ ½ÃÀåÀº 2023³âºÎÅÍ 2028³â±îÁö 6¾ï 4,315¸¸ ´Þ·¯, ¿¹Ãø ±â°£ µ¿¾È 4.49%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º» º¸°í¼´Â ½ÅÀå ÀÌ½Ä Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ Æ÷ÇÔÇÑ º¥´õ ºÐ¼® µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇϸç, CKD ¹× ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡, ¿©·¯ Á¦ÇüÀÇ ¾à¹° °¡¿ë¼º, ½ÅÀå À̽Ŀ¡¼ ¸é¿ª¾ïÁ¦Á¦¿¡ ´ëÇÑ ³ôÀº ÀÇÁ¸µµ µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2024
Á¾·á ¿¬µµ
2028
¿¹Ãø ±â°£
2024-2028
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³â ´ëºñ 2024³â
4.05%
CAGR
4.49%
ÁõºÐ ±Ý¾×
6¾ï 4,315¸¸ ´Þ·¯
ÀÌ º¸°í¼´Â ÇâÈÄ ¸î ³â µ¿¾È ½ÅÀå ÀÌ½Ä Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÒ ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ½ÅÀå À̽ÄÀ» À§ÇÑ »õ·Î¿î ±â¼úÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ½ÅÀåÀÌ½Ä °ü·Ã º¸Çè±Þ¿© Á¤Ã¥ ¹× Àü·«Àû Á¦ÈÞÀÇ Áõ°¡µµ ÀÌ ½ÃÀå¿¡ Å« ¼ö¿ä¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå »óȲ
Á¦3Àå ½ÃÀå ±Ô¸ð
½ÃÀå Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð 2023
½ÃÀå Àü¸Á 2023-2028
Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû
½ÅÀå ÀÌ½Ä Ä¡·áÁ¦ ¼¼°è ½ÃÀå 2018-2022
Á¦Ç°º° ºÎ¹® ºÐ¼® 2018-2022
À¯Åë ä³Îº° ºÎ¹® ºÐ¼® 2018-2022
Áö¿ªº° ºÎ¹® ºÐ¼® 2018-2022
±¹°¡º° ºÎ¹® ºÐ¼® 2018-2022
Á¦5Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
±¸¸ÅÀÚÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô Âü¿©¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀïÀÇ À§Çù
½ÃÀå »óȲ
Á¦6Àå ½ÃÀå ¼¼ºÐÈ : Á¦Ç°º°
½ÃÀå ºÎ¹®
ºñ±³ : Á¦Ç°º°
¼±ÅÃÀû »çÀÌÅäÄ«ÀÎ ¾ïÁ¦Á¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¸é¿ª ¾ïÁ¦¼º ´ë»ç ´ëÇ× ¹°Áú : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
±âŸ ¾àÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
½ÃÀå ±âȸ : Á¦Ç°º°
Á¦7Àå ½ÃÀå ¼¼ºÐÈ : À¯Åë ä³Îº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Åë ä³Îº°
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
½ÃÀå ±âȸ : À¯Åë ä³Îº°
Á¦8Àå °í°´ »óȲ
Á¦9Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦10Àå ÃËÁø¿äÀÎ, °úÁ¦ ¹× µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå µ¿Çâ
Á¦11Àå º¥´õ »óȲ
°³¿ä
º¥´õ »óȲ
È¥¶õ »óȲ
¾÷°è ¸®½ºÅ©
Á¦12Àå º¥´õ ºÐ¼®
´ë»ó º¥´õ
º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
AbbVie Inc.
Asahi Kasei Corp.
Astellas Pharma Inc.
Bristol Myers Squibb Co.
Dr Reddys Laboratories Ltd.
F. Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
Hansa Biopharma AB
Novartis AG
Organ Recovery Systems Inc.
Pfizer Inc.
Sanofi SA
Strides Pharma Science Ltd.
TFF Pharmaceuticals Inc.
TolerogenixX GmbH
Á¦13Àå ºÎ·Ï
ksm
Abstract
The kidney transplantation therapeutics market is forecasted to grow by USD 643.15 mn during 2023-2028, accelerating at a CAGR of 4.49% during the forecast period. The report on the kidney transplantation therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of CKD and renal impairments, availability of drugs in multiple dosage forms, and high dependency on immunosuppressants for kidney transplantation.
Market Scope
Base Year 2024
End Year 2028
Series Year 2024-2028
Growth Momentum Accelerate
YOY 2024 4.05%
CAGR 4.49%
Incremental Value $643.15mn
Technavio's kidney transplantation therapeutics market is segmented as below:
By Product
Selective cytokine inhibitors
Immunosuppressive antimetabolites
Other drug
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the novel techniques for kidney transplantation as one of the prime reasons driving the kidney transplantation therapeutics market growth during the next few years. Also, reimbursement policies for kidney transplantation and increasing strategic alliances will lead to sizable demand in the market.
The report on the kidney transplantation therapeutics market covers the following areas:
Kidney transplantation therapeutics market sizing
Kidney transplantation therapeutics market forecast
Kidney transplantation therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading kidney transplantation therapeutics market vendors that include AbbVie Inc., Asahi Kasei Corp., Astellas Pharma Inc., B.Braun SE, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius Medical Care AG and Co. KGaA, GlaxoSmithKline Plc, Hansa Biopharma AB, Novartis AG, Organ Recovery Systems Inc., Pfizer Inc., Sanofi SA, Strides Pharma Science Ltd., TFF Pharmaceuticals Inc., TolerogenixX GmbH, TransMedics Inc., and Transonic Systems Inc.. Also, the kidney transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global kidney transplantation therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global kidney transplantation therapeutics market 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Selective cytokine inhibitors - Market size and forecast 2023-2028
Exhibit 34: Chart on Selective cytokine inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Selective cytokine inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Selective cytokine inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Selective cytokine inhibitors - Year-over-year growth 2023-2028 (%)
6.4 Immunosuppressive antimetabolites - Market size and forecast 2023-2028
Exhibit 38: Chart on Immunosuppressive antimetabolites - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Immunosuppressive antimetabolites - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Immunosuppressive antimetabolites - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Immunosuppressive antimetabolites - Year-over-year growth 2023-2028 (%)
6.5 Other drug - Market size and forecast 2023-2028
Exhibit 42: Chart on Other drug - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Other drug - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Other drug - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Other drug - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Product
Exhibit 46: Market opportunity by Product ($ million)
Exhibit 47: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 48: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 49: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 50: Chart on Comparison by Distribution Channel
Exhibit 51: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacy - Market size and forecast 2023-2028
Exhibit 52: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacy - Market size and forecast 2023-2028
Exhibit 56: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacy - Market size and forecast 2023-2028
Exhibit 60: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 64: Market opportunity by Distribution Channel ($ million)
Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Canada - Market size and forecast 2023-2028
Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 115: AbbVie Inc. - Overview
Exhibit 116: AbbVie Inc. - Product / Service
Exhibit 117: AbbVie Inc. - Key news
Exhibit 118: AbbVie Inc. - Key offerings
12.4 Asahi Kasei Corp.
Exhibit 119: Asahi Kasei Corp. - Overview
Exhibit 120: Asahi Kasei Corp. - Business segments
Exhibit 121: Asahi Kasei Corp. - Key news
Exhibit 122: Asahi Kasei Corp. - Key offerings
Exhibit 123: Asahi Kasei Corp. - Segment focus
12.5 Astellas Pharma Inc.
Exhibit 124: Astellas Pharma Inc. - Overview
Exhibit 125: Astellas Pharma Inc. - Product / Service
Exhibit 126: Astellas Pharma Inc. - Key news
Exhibit 127: Astellas Pharma Inc. - Key offerings
12.6 Bristol Myers Squibb Co.
Exhibit 128: Bristol Myers Squibb Co. - Overview
Exhibit 129: Bristol Myers Squibb Co. - Product / Service
Exhibit 130: Bristol Myers Squibb Co. - Key news
Exhibit 131: Bristol Myers Squibb Co. - Key offerings
12.7 Dr Reddys Laboratories Ltd.
Exhibit 132: Dr Reddys Laboratories Ltd. - Overview
Exhibit 133: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 134: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 135: Dr Reddys Laboratories Ltd. - Segment focus
12.8 F. Hoffmann La Roche Ltd.
Exhibit 136: F. Hoffmann La Roche Ltd. - Overview
Exhibit 137: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 138: F. Hoffmann La Roche Ltd. - Key news
Exhibit 139: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 140: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 141: GlaxoSmithKline Plc - Overview
Exhibit 142: GlaxoSmithKline Plc - Business segments
Exhibit 143: GlaxoSmithKline Plc - Key news
Exhibit 144: GlaxoSmithKline Plc - Key offerings
Exhibit 145: GlaxoSmithKline Plc - Segment focus
12.10 Hansa Biopharma AB
Exhibit 146: Hansa Biopharma AB - Overview
Exhibit 147: Hansa Biopharma AB - Product / Service
Exhibit 148: Hansa Biopharma AB - Key offerings
12.11 Novartis AG
Exhibit 149: Novartis AG - Overview
Exhibit 150: Novartis AG - Business segments
Exhibit 151: Novartis AG - Key offerings
Exhibit 152: Novartis AG - Segment focus
12.12 Organ Recovery Systems Inc.
Exhibit 153: Organ Recovery Systems Inc. - Overview
Exhibit 154: Organ Recovery Systems Inc. - Product / Service
Exhibit 155: Organ Recovery Systems Inc. - Key offerings
12.13 Pfizer Inc.
Exhibit 156: Pfizer Inc. - Overview
Exhibit 157: Pfizer Inc. - Product / Service
Exhibit 158: Pfizer Inc. - Key news
Exhibit 159: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 160: Sanofi SA - Overview
Exhibit 161: Sanofi SA - Business segments
Exhibit 162: Sanofi SA - Key news
Exhibit 163: Sanofi SA - Key offerings
Exhibit 164: Sanofi SA - Segment focus
12.15 Strides Pharma Science Ltd.
Exhibit 165: Strides Pharma Science Ltd. - Overview
Exhibit 166: Strides Pharma Science Ltd. - Business segments
Exhibit 167: Strides Pharma Science Ltd. - Key offerings
Exhibit 168: Strides Pharma Science Ltd. - Segment focus
12.16 TFF Pharmaceuticals Inc.
Exhibit 169: TFF Pharmaceuticals Inc. - Overview
Exhibit 170: TFF Pharmaceuticals Inc. - Product / Service
Exhibit 171: TFF Pharmaceuticals Inc. - Key offerings
12.17 TolerogenixX GmbH
Exhibit 172: TolerogenixX GmbH - Overview
Exhibit 173: TolerogenixX GmbH - Product / Service
Exhibit 174: TolerogenixX GmbH - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 175: Inclusions checklist
Exhibit 176: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 177: Currency conversion rates for US$
13.4 Research methodology
Exhibit 178: Research methodology
Exhibit 179: Validation techniques employed for market sizing
Exhibit 180: Information sources
13.5 List of abbreviations
Exhibit 181: List of abbreviations